Margem de Segurança para Hiperviscosidade Plasmática para Prevenção de Trombose em Pacientes com Doença Cardiovascular após Vacinação contra COVID-19

People having hematological disorders and hypercoagulability state need extra precautions because of the increased risk of thrombosis after COVID-19 vaccination

“…Moreover, hyperviscosity syndrome (HVS) is a rare syndrome characterized by high immunoglobins and proteins, which cause an increase in blood thickness. Plasma hyperviscosity has been found in both COVID-19 infection and after vaccination, correlated with disease severity; therefore, people with HVS syndrome can be more vulnerable to COVID-19 infection and vaccination ( 53 , 54 ).…”